Mark Caulfield graduated in Medicine in 1984 from the London Hospital Medical College and trained in Clinical Pharmacology at St Bartholomew’s Hospital where he developed a research programme in molecular genetics of hypertension and clinical research. In 2009, he won the Lily Prize of the British Pharmacology Society. Since 2008, he directs the Barts National Institute of Health Research Cardiovascular Biomedical Research Unit. He was appointed Director of the William Harvey Research Institute in 2002 and elected to the Academy of Medical Sciences in 2008, and was President of the British Hypertension Society (2009-2011). He served on the NICE Guideline Group for hypertension. Since 1996, he has been National Co-ordinator of the MRC British Genetics of Hypertension (BRIGHT) Study on behalf of 5 UK Universities. He was on the Steering Group of the Anglo-Scandinavian Cardiac Outcome Trial recruiting 1157 hypertensives.This trial has changed international guidance on lipid lowering and high blood pressure treatment. In 2007, 2009 and 2011 his research has been independently rated amongst the top ten scientific discoveries in his field.
Alexandre Persu is professor of Medicine, specialist in Hypertension and Nephrology, head of the Hypertension outpatient clinic and Chef de Clinique in Cardiology at the Cliniques Universitaires Saint-Luc, Catholic University of Louvain, Brussels, Belgium. He is also secretary of the Belgian Hypertension Committee (BHC), member of the Editorial Board of the European Journal of Clinical Investigation and former member of the Editorial Board of the Journal of Hypertension. Currently, his main research interests are resistant and secondary hypertension.
Professor Toshiro Fujita is Professor of the Department of Clinical Epigenetics, RCAST, the University of Tokyo and Director, CREST, JST Strategic Basic Research Program. He qualified in medicine in 1972 at the Keio University School of Medicine in Japan.
His contribution to the study of hypertension and kidney diseases has been widely recognized. In 1980, Fujita and Bartter at NIH demonstrated the pathogenesis of salt-sensitive hypertension. Dr. Fujita’s group has reported the involvement of aldosterone/mineralocorticoid receptor activation in salt-sensitive hypertension and metabolic syndrome.
Professor Fujita has been actively contributing to professional associations and scientific publications. Over the past 30 years, Professor Fujita has published more than 600 scientific articles. In 2013, he was awarded ESH Honorary Membership Award, European Society of Hypertension (ESH) and the International Award of Okamoto. In 2014, he received Franz Volhard Award from the International Society of Hypertension (ISH) and the Excellence Award for Hypertension Research from the Council for Hypertension, AHA. He was President of the Japanese Society of Hypertension, the Japanese Society of Internal Medicine, the Japanese Society of Endocrinology, and the Japanese Society of Nephrology. Since 2003, he has been involved in High Blood Pressure Council (HBPR), and is currently a member of HBPR Leadership Committee.
Keith C. Ferdinand
Keith C. Ferdinand, MD, is Professor of Medicine at the Tulane University School of Medicine in New Orleans, Louisiana. He is board-certified in internal medicine and cardiovascular disease, certified in the subspecialty of nuclear cardiology, and a specialist in clinical hypertension certified by the American Society of Hypertension. Dr. Ferdinand is Immediate Past Chair of the National Forum for Heart Disease and Stroke Prevention. As an investigator, Dr. Ferdinand has conducted numerous trials and widely published in the fields of cardiology, cardiovascular disease, hypertension, lipids and cardio metabolic risk, especially in racial and ethnic minorities. In 2015, he was the Editor of the book, “Hypertension in High Risk African Americans”, published by Springer. In 2004, Dr. Ferdinand received the Louis B. Russell, Jr. Memorial Award of the American Heart Association and in 2010, the Walter M. Booker Community Service Award of the Association of Black Cardiologists, of which he is past Chair and Chief Science Officer. He has been recognized by the Congressional Black Caucus Health Trust with an award for journalism, as well as the Charles Drew award for medical excellence in conjunction with the National Minority Quality Foundation. In 2015, Dr. Ferdinand was inducted into the Association of University Cardiologists.
Dr. Henry Black is currently a member of the International Society of Hypertension and was a former President of the American Society of Hypertension. He has held faculty positions at Yale and Rush University. Dr. Black also served as a member of the Food and Drug Administration CardioRenal Advisory Committee. Dr. Black has participated in and been in a leadership role in several landmark clinical trials including the Systolic Hypertension in the Elderly Program (SHEP), the Antihypertensive and Lipid Lower Trial to Prevent Heart Attack (ALLHAT), CONVINCE, and the Women’s Health Initiative (WHI). He has published more than 400 papers, chapters and reviews and is an author or co-author on more than 220 abstracts. Dr. Black holds an A.B. degree from the Columbia University and an M.D. from the New York University School of Medicine. He completed his residency in internal medicine at Johns Hopkins University and Yale University.
Dr. Howard Dittrich currently serves as an Entrepreneur-in-Residence for Frazier Healthcare Partners, Chief Medical Officer of Hawkeye Therapeutics (a Frazier Healthcare financed “searchco”), and consulting Chief Medical Officer at Leading Biosciences. He is a cardiologist with more than 20 years of experience in cardiovascular research and clinical development. In addition, Dr. Dittrich co-founded and serves as Chairman of the board of directors of IOWA Approach Inc., privately-held company developing atrial fibrillation ablation technology, and President and Board member of Advanced Endovascular Therapeutics, an early stage device company focused on novel coating technology for endovascular devices. He also serves as director for Mast Therapeutics, Inc., a US public biotechnology company. Previously, Dr. Dittrich held executive positions overseeing clinical development and regulatory affairs at Sorbent Therapeutics, NovaCardia, Inc, and Molecular Biosystems, Inc. and Alliance Pharmaceutical Corp., during which time he was involved in gaining U.S. FDA approval for two cardiovascular imaging agents. He held a faculty position at University of California San Diego (UCSD) in the Department of Medicine and Division of Cardiology. Dr. Dittrich holds a B.S. degree from the University of Iowa and an M.D. from the University Of Iowa Carver College Of Medicine. He completed his residency in internal medicine and clinical fellowship in cardiology at UCSD.
Professor Frans Leenen, MD, PhD, FRCPC, FAHA, is the Director of the Hypertension Clinical and Research Program at the University of Ottawa Heart Institute. He is also Professor of Medicine and Pharmacology in the Department of Medicine and the Department of Cellular and Molecular Medicine at the University of Ottawa.
He is an internationally recognised specialist in the study of the sympathetic nervous system and his research focuses on the role of brain mechanisms in hypertension and congestive heart failure and how these can be inhibited by drug therapy. He was one of the lead trial investigators for ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial), the largest study ever conducted in people suffering from hypertension, with more than 42,000 volunteers participating in 600 centres throughout Canada and the United States. He has authored more than 300 scientific publications, many of which have appeared in prestigious journals.